U.S. markets close in 1 hour 23 minutes

Sorrento Therapeutics, Inc. (SRNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.57-0.05 (-0.83%)
As of 2:37PM EDT. Market open.

Sorrento Therapeutics, Inc.

4955 Directors Place
San Diego, CA 92121
United States
858 203 4100

Full Time Employees502

Key Executives

NameTitlePayExercisedYear Born
Dr. Henry H. JiCo-Founder, Chairman, CEO & Pres1.19MN/A1964
Mr. Najjam AsgharSr. VP & CFO351.69kN/A1982
Mr. Brian SunSr. VP, Gen. Counsel & Corp. Sec.N/AN/AN/A
Mr. William J. FarleyVP of Sales & Bus. Devel.N/AN/AN/A
Dr. Michael A. RoyalSVP & Chief Medical OfficerN/AN/A1954
Dr. Alexis NahamaSr. VP & Head of RTX ProgramN/AN/AN/A
Dr. Mark R. BrunswickSr. VP of Regulatory AffairsN/AN/AN/A
Dr. Shawn Sahebi Ph.D.Sr. VP of Strategy & AnalyticsN/AN/AN/A
Mr. Brian CooleySr. VP of Lymphatic Drug Delivery BU LeaderN/AN/AN/A
Dr. Robert D. Allen Ph.D.Sr. VP of Antiviral & ImmunotherapyN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Corporate Governance

Sorrento Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.